Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Pancreatic Cancer: Molecular Targets for Therapy

  • Steven N. Hochwald
  • William G. Cance
  • Elena Kurenova
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4358-4


Pancreatic cancer, synonym pancreas cancer, is a virulent disease with no effective therapy besides surgical resection. The possibility for surgical tumor removal is limited by early metastatic spread of tumor to sites outside the pancreas. The survival for patients with metastatic pancreatic cancer is less than 1 year following diagnosis. Clinicians must translate the available knowledge of the molecular basis of this disease into rationale and effective therapeutic strategies for treatment.

Pancreas cancer is one of the tumors with the highest number of genetic mutations of any solid malignancy. These include oncogenes, tumor suppressor genes, and DNA-stability genes. The stability genes include mismatch repair (MMR) and base excision repair (BER) genes, which control the mutation rate of other genes. A number of genetic alterations have been, and still are being, tested as molecular target for antipancreatic cancer therapy. It is clear that novel molecular targets and...


Epidermal Growth Factor Receptor Pancreatic Cancer Focal Adhesion Kinase Pancreatic Cancer Cell Pancreatic Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Aho U, Zhao X, Lohr M et al (2007) Molecular mechanisms of pancreatic cancer and potential targets of treatment. Scand J Gastroenterol 42:279–296CrossRefPubMedGoogle Scholar
  2. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167CrossRefPubMedPubMedCentralGoogle Scholar
  3. Cohenuram M, Said M (2007) Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and future. JOP 8:4–15PubMedGoogle Scholar
  4. Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, … Biasco G (2016) State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 8(1), 55–66. doi:10.4251/wjgo.v8.i1.55CrossRefPubMedPubMedCentralGoogle Scholar
  5. Hansel DE, Kern SE, Hruban RH (2003) Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4:237–256CrossRefPubMedGoogle Scholar
  6. Kindler HL, Friberg G, Siingh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040CrossRefPubMedGoogle Scholar
  7. Matsuoka T, Yashiro M (2016) Molecular targets for the treatment of pancreatic cancer: clinical and experimental studies. World J Gastroenterol 22(2):776–789. doi:10.3748/wjg.v22.i2.776CrossRefPubMedPubMedCentralGoogle Scholar
  8. Sulzmaier FJ, Jean C, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14:598–610. doi:10.1038/nrc3792CrossRefPubMedPubMedCentralGoogle Scholar
  9. Wallace JA, Locker G, Nattam S et al (2007) Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. Program and abstracts of the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 17–21 Jan Orlando (Abstract 127)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Steven N. Hochwald
    • 1
  • William G. Cance
    • 1
  • Elena Kurenova
    • 1
  1. 1.Departments of Surgical OncologyRoswell Park Cancer InstituteBuffaloUSA